Trial Profile
A Randomised Open-Label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-Line NNRTI/2N(t)RTI Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Lopinavir/ritonavir; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SECOND-LINE
- 16 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record .
- 06 Aug 2013 Bone metabolism substudy results published in AIDS.
- 03 Jul 2013 Bone metabolism substudy presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.